These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34347883)

  • 1. Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
    Dolton MJ; Chesterman A; Moein A; Sink KM; Waitz A; Blondeau K; Kerchner GA; Hu N; Brooks L; Wetzel-Smith MK; Roden A; Deshmukh A; Peng K; Carrasco-Triguero M; Smith J; Ostrowitzki S; Quartino A
    Clin Pharmacol Ther; 2021 Nov; 110(5):1337-1348. PubMed ID: 34347883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
    Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
    Harb G; Lebel F; Battikha J; Thackara JW
    Curr Med Res Opin; 2010 Feb; 26(2):279-88. PubMed ID: 19947907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
    Morcos PN; Zhang X; McIntyre C; Bittner B; Rowell L; Hussain Z
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):537-48. PubMed ID: 23547849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.
    Li Z; Nagy A; Lindner D; Duff K; Garcia E; Ay H; Rondon JC; Yel L
    J Clin Immunol; 2024 Jun; 44(7):148. PubMed ID: 38896141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.
    Printz MA; Dychter SS; DeNoia EP; Harrigan R; Sugarman BJ; Zepeda M; Souratha J; Kang DW; Maneval DC
    Curr Ther Res Clin Exp; 2020; 93():100604. PubMed ID: 32963641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
    Shpilberg O; Jackisch C
    Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
    Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
    Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
    Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
    J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
    Muchmore DB; Vaughn DE
    J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
    Guthrie H; Honig LS; Lin H; Sink KM; Blondeau K; Quartino A; Dolton M; Carrasco-Triguero M; Lian Q; Bittner T; Clayton D; Smith J; Ostrowitzki S
    J Alzheimers Dis; 2020; 76(3):967-979. PubMed ID: 32568196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.
    Yang Y; Qiu H; Fan Y; Zhang Q; Qin H; Wu J; Zhang X; Liu Y; Zhou R; Zhang Q; Ye Z; Ma J; Xu Y; Feng S; Fei Y; Li N; Cui X; Dong F; Wang Q; Shen K; Shakib S; Williams J; Hu W
    Alzheimers Res Ther; 2024 Oct; 16(1):218. PubMed ID: 39390616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
    Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
    Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
    Dychter SS; Ebel D; Mead TR; Yocum RC
    Curr Ther Res Clin Exp; 2009 Dec; 70(6):421-38. PubMed ID: 24692835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.
    Vaughn DE; Muchmore DB
    Endocr Pract; 2011; 17(6):914-21. PubMed ID: 22138081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
    Thomas JR; Yocum RC; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats.
    Styles IK; Feeney OM; Nguyen TH; Brundel DHS; Kang DW; Clift R; McIntosh MP; Porter CJH
    J Control Release; 2019 Dec; 315():85-96. PubMed ID: 31655131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration.
    Allen CH; Etzwiler LS; Miller MK; Maher G; Mace S; Hostetler MA; Smith SR; Reinhardt N; Hahn B; Harb G;
    Pediatrics; 2009 Nov; 124(5):e858-67. PubMed ID: 19805455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.